SCHEMBL30497306

SCHEMBL30497306

O=C(O)c1ccc2ncn(Cc3ccsn3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.47
▸ PLA2G4A P47712 1/20 0.41
▸ TBXA2R P21731 1/20 0.41
▸ F2 P00734 2/20 0.41
▸ F10 P00742 2/20 0.41
▸ PRSS1 P07477 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PABPC1 P11940 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HCAR3 P49019 1/20 0.39
▸ PKM P14618 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497262 0.80 FGFR1 (0.47) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL30497324 0.79 FGFR1 (0.54) FGFR1TBXA2RF2F10PRSS1
SCHEMBL30497301 0.78 FGFR1 (0.56) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL1608848 0.78 CYP11B1 (0.60) FGFR1F2F10PRSS1MEN1
SCHEMBL30497328 0.78 FGFR1 (0.47) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL29555663 0.78 FGFR1 (0.47) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL28719177 0.77 FGFR1 (0.49) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL29424766 0.77 FGFR1 (0.49) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL3838757 0.76 FGFR1 (0.56) FGFR1PLA2G4ATBXA2RF2F10
SCHEMBL13508660 0.75 CYP11B1 (0.57) FGFR1PLA2G4ATBXA2RMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
US-20230391747-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-12-07 — — US disclosed
US-11702404-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2023-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702404-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 FGFR1 987/4885PLA2G4A 971/4885TBXA2R 66/4885
US-20230391747-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 FGFR1 987/4885PLA2G4A 971/4885TBXA2R 66/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 FGFR1 987/4885PLA2G4A 971/4885TBXA2R 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback